FDA approves combination therapy for non-small lung cancer
Drug Discovery World
AUGUST 22, 2024
The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
Let's personalize your content